SML1072
GSK-LSD1
≥98% (HPLC), lysine specific demethylase 1 (LSD1) inhibitor, powder
Synonyme(s) :
GSK-LSD1 (trans-racemic) dihydrochloride, rel- N-[(1R,2S)-2-Phenylcyclopropyl]-4-Piperidinamine hydrochloride (1:2)
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
A propos de cet article
Formule empirique (notation de Hill) :
C14H20N2 · 2HCl
Numéro CAS:
Poids moléculaire :
289.24
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderService technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderNom du produit
GSK-LSD1, ≥98% (HPLC)
SMILES string
C1(N[C@@H]2C[C@H]2C3=CC=CC=C3)CCNCC1
InChI
1S/C14H20N2/c1-2-4-11(5-3-1)13-10-14(13)16-12-6-8-15-9-7-12/h1-5,12-16H,6-10H2/t13-,14+/m0/s1
InChI key
BASFYRLYJAZPPL-UONOGXRCSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
H2O: 20 mg/mL, clear
storage temp.
2-8°C
Quality Level
Catégories apparentées
Application
GSK-LSD1 has been used as a lysine specific demethylase 1 (LSD1) inhibitor in mice to study sepsis-induced mortality. It has also been used as an inhibitor to study if the effect of phenelzine activation of human immunodeficiency virus (HIV) latency is caused due to LSD1.
Biochem/physiol Actions
GSK-LSD1 is a potent and selective inhibitor of lysine specific demethylase 1 (LSD1). GSK-LSD1 potently inhibits proliferation of varies cancer cell lines by changing gene expression patterns. For full characterization details, please visit the GSK-LSD1 probe summary on the Structural Genomics Consortium (SGC) website.
To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc
To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc
GSK-LSD1 is a potent and selective inhibitor of lysine specific demethylase 1.
Features and Benefits
GSK-LSD1 is an epigenetic chemical probe available through a partnership with the Structural Genomics Consortium (SGC). To learn more and view other SGC epigenetic probes, visit sigma.com/SGC.
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency
Llewellyn GN, et al.
Journal of Neurovirology, 1-12 (2017)
PKCα-LSD1-NF-κB-Signaling Cascade Is Crucial for Epigenetic Control of the Inflammatory Response
Kim D, et al.
Molecular Cell, 69(3), 398-411 (2018)
Bastian Ramms et al.
Diabetes, 71(12), 2513-2529 (2022-09-27)
The transition from lean to obese states involves systemic metabolic remodeling that impacts insulin sensitivity, lipid partitioning, inflammation, and glycemic control. Here, we have taken a pharmacological approach to test the role of a nutrient-regulated chromatin modifier, lysine-specific demethylase (LSD1)
Lysine-specific demethylase 1A restricts ex vivo propagation of human HSCs and is a target of UM171.
Agatheeswaran Subramaniam et al.
Blood, 136(19), 2151-2161 (2020-06-26)
Culture conditions in which hematopoietic stem cells (HSCs) can be expanded for clinical benefit are highly sought after. Here, we report that inhibition of the epigenetic regulator lysine-specific histone demethylase 1A (LSD1) induces a rapid expansion of human cord blood-derived
Shinji Takagi et al.
Cancer research, 77(17), 4652-4662 (2017-07-02)
T-3775440 is an irreversible inhibitor of the chromatin demethylase LSD1, which exerts antiproliferative effects by disrupting the interaction between LSD1 and GFI1B, a SNAG domain transcription factor, inducing leukemia cell transdifferentiation. Here, we describe the anticancer effects and mechanism of
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique